A study of 260 patients with Crohns disease finds that vedolizumab led to significantly better clinical remission rates as compared with patients who were treated with anti–tumor necrosis factor therapy. ECCO2023
COPENHAGEN — A study of 260 patients with Crohn's disease finds that vedolizumab led to significantly better clinical remission rates as compared with patients who were treated with anti–tumor necrosis factor therapy.
After 2 years, approximately 83% of patients who were treated with vedolizumab were still receiving treatment, but only 56% of patients who received anti-TNF therapy were still undergoing therapy with either adalimumab or infliximab. After 2 years of treatment, 64.2% of patients who were treated with vedolizumab were in clinical remission, compared with 44.7% of patients who were treated with anti-TNF therapy. And, 62.
From 45 treatment centers across Germany, researchers prospectively enrolled 1,200 biologic-naive and biologic-experienced patients with either Crohn's disease or ulcerative colitis between 2017 and 2020 into the VEDOIBD study. This analysis was limited to 260 patients with Crohn's disease. "We often lose patients because they develop anti-drug antibodies, but also due to escape mechanisms, as well as dermatological side effects including psoriasis which is really annoying for patients. We also find that anti-TNF drugs just stop working after 12-18 months, and then we need to use steroids which patients dislike," he said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AI Helps Predict Ulcerative Colitis Remission/Activity, Flare-upsAn AI tool can distinguish histological remission from activity in biopsies of UC and predict flare-ups -- and could have a role in both clinical trials and routine practice.
Read more »
Inflation cooled to 6% in February as the Federal Reserve weighs next steps on interest ratesPrices rose 0.4% last month from January, slightly lower than the prior monthly increase, as investors assess how the Fed may respond to the twin challenges of inflation and unrest in the banking sector when it meets next week.
Read more »
Xcel Energy, utility leaders face Colorado lawmakers questions on rising ratesLeaders from Xcel Energy and other utility companies will face questions from Colorado lawmakers today on causes behind recent bill spikes. And the special committee wants to hear from you. MORE:
Read more »
Fed seen raising rates by 25 bps next week and in MayThe Federal Reserve is seen raising its benchmark rate a quarter of a percentage point next week and again in May, as a government report showed U.S. inflation remained high in February, and concerns of a long-lasting banking crisis eased.
Read more »
Amid 2 stunning bank failures, Fed expected to raise interest ratesAfter two banks collapsed over the weekend, many Americans are now concerned about the security of U.S. financial institutions.
Read more »
Scientists Warn: Common Cleaning Chemical Linked to 500% Increased Risk of Parkinson’s DiseaseA common and widely used chemical may be fueling the rise of the world’s fastest-growing brain condition – Parkinson’s disease. For the past 100 years, trichloroethylene (TCE) has been used to decaffeinate coffee, degrease metal, and dry clean clothes. It contaminates the Marine Corps base Camp Leje
Read more »